Traffic:
10E
10W
15N
15S
57N
57S
60E
60W
210E
210W
This Site
Web Search
powered by
YAHOO! SEARCH
Subscriber Services
|
Home Delivery
|
e-Edition
|
Alerts
|
RSS
Home
News
Ontario
Rancho Cucamonga
Pomona
Upland
Claremont
Montclair
Chino Valley
California
Crime & Public Safety
Elections
Education
S.B. County Watch
Upland Watch
I.E.: Medicare Testing Ground
Sports
Buy Event Tickets Now
Golf - Tee Times and Courses
Preps
Reign Hockey
Rancho Cucamonga Quakes
Local Colleges
USC
UCLA
Lakers
Clippers
Dodgers
Angels
Ducks
Soccer
Motor Sports
Horse Racing
Live Odds
Business
Autos
Real Estate News
Technology
Opinions
Editorial
Letters
Columnists
Blogs
LA.COM
Buy Tickets
Movies
TV
Music
Shopping & Beauty
Recreation
Neighborhood
Arts
Living
Dining
Find A Restaurant
Lottery
Horoscopes
Travel
Trevor's Travels
Health
Crossword Puzzle
Local Casinos
Foothills Magazine
Info
Subscribe For Home Delivery
Contact Us
RSS
Podcast
Subscriber Services
Place An Ad
NIE
Classified
Place an Ad
Homes
Jobs
Auto
Search autos
Buy/Sell a car
Research/Financing a car
Find a dealer
Shopping
This week's ads
Obits
Directories
Local Business
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ultragenyx Pharmaceutical Inc.
< Previous
1
2
3
Next >
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Today 16:30 EDT
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
October 07, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Provides Update on Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
October 03, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Upcoming Setrusumab (UX143) Presentations at the ASBMR 2024 Annual Meeting
September 26, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
September 18, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Participate in Investor Conferences in September
August 29, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
August 01, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
July 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
July 24, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
July 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Plans to File for Accelerated Approval of UX111 for the Treatment of Sanfilippo Syndrome Type A (MPS IIIA)
June 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx and Mereo BioPharma Announce New Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Sustained Reductions in Fracture Rates Following Treatment with Setrusumab (UX143) in Patients with Osteogenesis Imperfecta (OI)
June 11, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
MREO
RARE
Ultragenyx to Participate at Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Positive Top-Line Results from Phase 3 Study of DTX401 Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
May 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
May 17, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference
May 07, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update
May 02, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Issues 2023 Corporate Responsibility Report, Showcasing Commitment to Improving Equity and Access to Innovation in Rare Disease
April 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
April 30, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update
April 25, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
April 19, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
April 15, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
April 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
April 12, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
March 22, 2024
From
Ultragenyx Pharmaceutical Inc.
Via
GlobeNewswire
Tickers
RARE
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Privacy Policy
|
Terms of Use
|
MNG Corporate Site Map
|
Copyright